SpringerLink
Log in

Evaluating prostate cancer bone metastases response with whole-body MRI: What we know and still need to know

  • Commentary
  • Published:
European Radiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

ARTA:

Androgen receptor targeting agents

CT-BS:

Computed tomography and bone scintigraphy

mCRPC:

Metastatic castration-resistant prostate cancer

mHSPC:

Metastatic hormone sensitive prostate cancer

PSA:

Prostate-specific antigen

PSMA:

Prostate-specific membrane antigen

RAC:

Response assessment category

WB-MRI:

Whole-body magnetic resonance imaging

References

  1. Gillessen S, Omlin A, Attard G et al (2019) Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 30:e3. https://doi.org/10.1093/annonc/mdw180

    Article  CAS  PubMed  Google Scholar 

  2. Batra A, Glick D, Valdes M (2024) Contemporary systemic therapy intensification for prostate cancer: a review for general practitioners in oncology. Curr Oncol 31:1047–1062. https://doi.org/10.3390/curroncol31020078

    Article  PubMed  PubMed Central  Google Scholar 

  3. Quintanal-Villalonga Á, Chan JM, Yu HA et al (2020) Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol 17:360–371. https://doi.org/10.1038/s41571-020-0340-z

    Article  PubMed  PubMed Central  Google Scholar 

  4. Armstrong AJ, Mottet N, Iguchi T et al (2022) Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES. J Clin Oncol 40:5072–5072. https://doi.org/10.1200/JCO.2022.40.16_suppl.5072

    Article  Google Scholar 

  5. Bryce AH, Chen YH, Liu G et al (2020) Patterns of cancer progression of metastatic hormone-sensitive prostate cancer in the ECOG3805 CHAARTED Trial. Eur Urol Oncol 3:717–724. https://doi.org/10.1016/j.euo.2020.07.001

    Article  PubMed  PubMed Central  Google Scholar 

  6. Robbrecht DG, Delanoy N, Tannock IF et al (2020) Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. Eur J Cancer 125:142–152. https://doi.org/10.1016/j.ejca.2019.10.029

    Article  CAS  PubMed  Google Scholar 

  7. Bryce AH, Alumkal JJ, Armstrong A et al (2017) Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis 20:221–227. https://doi.org/10.1038/pcan.2016.71

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Schaeffer EM, Srinivas S, Adra N et al (2023) Prostate cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 21:1067–1096. https://doi.org/10.6004/jnccn.2023.0050

    Article  CAS  PubMed  Google Scholar 

  9. Rao A, Scher HI, De Porre P et al (2020) Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. ESMO Open 5:1–9. https://doi.org/10.1136/esmoopen-2020-000943

    Article  Google Scholar 

  10. Perez-Lopez R, Tunariu N, Padhani AR et al (2019) Imaging diagnosis and follow-up of advanced prostate cancer: clinical perspectives and state of the art. Radiology 292:273–286. https://doi.org/10.1148/radiol.2019181931

    Article  PubMed  Google Scholar 

  11. Gafita A, Rauscher I, Weber M et al (2022) Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med 1:2003–2005. https://doi.org/10.2967/jnumed.121.263072

    Article  CAS  Google Scholar 

  12. Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71:81–92. https://doi.org/10.1016/j.eururo.2016.05.033

    Article  PubMed  PubMed Central  Google Scholar 

  13. Trabulsi EJ, Rumble RB, Jadvar H et al (2020) Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol 38:1963–1996. https://doi.org/10.1200/JCO.19.02757

    Article  CAS  PubMed  Google Scholar 

  14. Garcia-Ruiz A, Macarro C, Zacchi F et al (2024) Whole-body magnetic resonance imaging as a treatment response biomarker in castration-resistant prostate cancer with bone metastases: the iPROMET clinical trial. Eur Urol. https://doi.org/10.1016/j.eururo.2024.02.016

  15. Garcia-Ruiz A, Macarro C, Mateo J, Perez-Lopez R (2024) Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh’s Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration r. Eur Urol. https://doi.org/10.1016/j.eururo.2024.05.011

  16. Dalla Volta A, Valcamonico F, Zivi A et al (2024) Whole-body diffusion-weighted magnetic resonance imaging for assessment of the bone response rate in patients with metastatic hormone-sensitive prostate cancer receiving enzalutamide. Eur Urol 4–7. https://doi.org/10.1016/j.eururo.2024.05.004

  17. Donners R, Figueiredo I, Tunariu N et al (2022) Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing. Eur Radiol 32:4647–4656. https://doi.org/10.1007/s00330-022-08536-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Donners R, Figueiredo I, Westaby D et al (2023) Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer. Cancer Imaging 23:121. https://doi.org/10.1186/s40644-023-00644-w

    Article  PubMed  PubMed Central  Google Scholar 

  19. Tunariu N, Avesani G, Russo L et al (2024) No METRADS-P vs. RECIST/PCWG criteria to detect disease progression in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol (Meeting Abstr 42:Abstract 5070). https://doi.org/10.1200/JCO.2024.42.16_suppl.5070

  20. Elgendy K, Barwick TD, Auner HW et al (2022) Repeatability and test–retest reproducibility of mean apparent diffusion coefficient measurements of focal and diffuse disease in relapsed multiple myeloma at 3T whole body diffusion-weighted MRI (WB-DW-MRI). Br J Radiol 95. https://doi.org/10.1259/bjr.20220418

  21. Eveslage M, Rassek P, Riegel A et al (2023) Diffusion-weighted MRI for treatment response assessment in osteoblastic metastases-A repeatability study. Cancers (Basel) 15:1–16. https://doi.org/10.3390/cancers15153757

    Article  Google Scholar 

  22. Pricolo P, Ancona E, Summers P et al (2020) Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels. Cancer Imaging 20:77. https://doi.org/10.1186/s40644-020-00350-x

    Article  PubMed  PubMed Central  Google Scholar 

  23. Belotti A, Ribolla R, Crippa C et al (2023) Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma. Am J Hematol 98:E230–E232. https://doi.org/10.1002/ajh.26995

    Article  CAS  PubMed  Google Scholar 

  24. Kosmin M, Padhani AR, Gogbashian A et al (2020) Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiology 297:622–629. https://doi.org/10.1148/radiol.2020192683

    Article  PubMed  Google Scholar 

Download references

Funding

The authors state that this work has not received any funding.

Author information

Authors and Affiliations

  1. Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, United Kingdom

    Anwar R. Padhani

  2. Clinical Radiology, The Royal Marsden NHS Foundation Trust, London, UK

    Nina Tunariu

  3. Institute of Cancer Research, Downs Road, Sutton, United Kingdom

    Nina Tunariu

  4. Radiomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

    Raquel Perez-Lopez

  5. Department of Surgery, Institut du Cancer Roi Albert II (IRA2) - Institut de Recherche Expérimentale & Clinique (IREC) – UCLouvain – Cliniques Universitaires Saint Luc, Brussels, Belgium

    Betrand Tombal

  6. Department of Medical Imaging, Institut du Cancer Roi Albert II (IRA2) - Institut de Recherche Expérimentale & Clinique (IREC) – UCLouvain – Cliniques Universitaires Saint Luc, Brussels, Belgium

    Frederic E. Lecouvet

Authors
  1. Anwar R. Padhani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nina Tunariu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raquel Perez-Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Betrand Tombal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frederic E. Lecouvet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anwar R. Padhani.

Ethics declarations

Guarantor

The scientific guarantor of this publication is Prof. Anwar R. Padhani.

Conflict of interest

The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Informed consent

Written informed consent was not required.

Ethical approval

Institutional Review Board approval was not required.

Study subjects or cohorts overlap

Not applicable

Methodology

  • Commentary

Additional information

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Padhani, A.R., Tunariu, N., Perez-Lopez, R. et al. Evaluating prostate cancer bone metastases response with whole-body MRI: What we know and still need to know. Eur Radiol (2024). https://doi.org/10.1007/s00330-024-10864-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00330-024-10864-8

Search

Navigation